Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05173896
PHASE2

Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial

Sponsor: Christina Kruuse

View on ClinicalTrials.gov

Summary

In a randomized controlled trial the feasibility and effect of three months treatment with daily tadalafil, on cerebral blood flow/reactivity and cognition, is investigated in patients with cerebral small vessel disease.

Key Details

Gender

All

Age Range

50 Years - Any

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2022-05-31

Completion Date

2029-12

Last Updated

2024-12-09

Healthy Volunteers

No

Interventions

DRUG

Tadalafil 20 MG

Daily dose of oral over-encapsulated tadalafil tablets (20 mg) for three months.

DRUG

Placebo

Daily dose of oral over-encapsulated placebo tablets for three months.

Locations (2)

Department of Neurology, Herlev Gentofte Hospital

Herlev, Denmark

Danish Research Centre for Magnetic Resonance

Hvidovre, Denmark